BioMarin Pharma (BMRN) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +1,016.7%
Financial Fact:
Intangible asset amortization and contingent consideration: 9.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.32), in-line with the analyst estimate of ($0.32). Revenue for the quarter came in at $449.8 million versus the consensus estimate of $442.09 million.
GUIDANCE:
BioMarin Pharma sees FY2022 revenue of $2.05-2.15 billion, versus the consensus of $2.14 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Asana, Inc. (ASAN) Tops Q2 EPS by 1c; offers guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
